PepDiana
Back to Evidence
Primary experimental recordPositive observation

PMC13133793::ACT044549

LCKLSL

Evidence text

Paper-level observation

the 5 μg/ml concentration exhibited the strongest inhibitory effect with only 1.8% RNV area (Figure 1A, C, and D).
textConfidence: medium

Assay observation

Activity
Metabolic/Cardiovascular
Subtype
Anti-angiogenic
Measure
percent_inhibition
Comparator
=
Raw observation
1.8%
Normalized measurement
=1.8%
Value minimum
Not reported by source
Value maximum
Not reported by source
Target
Mus musculus
Assay method
Not reported by source
Sequence
LCKLSL
Standardization
ready simple

Source publication

Study on the Role of Short Peptide LCKLSL Targeting ANXA2 in Retinal Neovascularization.

In Vivo · 2026

DOI 10.21873/invivo.14291 PMC13133793
Parent mention

Related peptide identities

PEPDIA-PLP-001707

Release PepDiana-V1-20260620. The stable record URL can be cited directly in supplementary material and downstream analyses.